Epratuzumab: all 27 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus ErythematosusCompletedNCT01408576Phase 3Results posted
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus ErythematosusCompletedNCT01262365Phase 3Results posted
- Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)CompletedNCT01261793Phase 3Results posted
- S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT00945815Phase 2Results posted
- Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)TerminatedNCT00941928Phase 2Results posted
- Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin LymphomaCompletedNCT00553501Phase 2Results posted
- Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell LymphomaCompletedNCT00301821Phase 2Results posted
- Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)CompletedNCT00098839Phase 1/2Results posted
- Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the BloodCompletedNCT02306629Phase 1
- International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010CompletedNCT01802814Phase 3
- Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) SubjectsCompletedNCT01534403Phase 2
- Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)CompletedNCT01449071Phase 1/2
- Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+Status unknownNCT01354457Phase 1/2
- Multi-centric StudyCompletedNCT01219816Phase 2
- Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active DiseaseCompletedNCT00660881Phase 2
- Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active DiseaseCompletedNCT00624351Phase 2
- Study of Epratuzumab in Systemic Lupus ErythematosusCompletedNCT00383513Phase 2
- Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)TerminatedNCT00383214Phase 3
- Study of Epratuzumab in Systemic Lupus ErythematosusWithdrawnNCT00382837Phase 3
- Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)TerminatedNCT00113971Phase 2
- Study of Epratuzumab (hLL2) in Patients With Waldenstrom's MacroglobulinemiaTerminatedNCT00113802Phase 2
- Study of Epratuzumab in Systemic Lupus ErythematosusTerminatedNCT00111306Phase 3
- Study of 90Y-hLL2 to Treat Non-Hodgkin's LymphomaTerminatedNCT00054834Phase 1
- Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)CompletedNCT00044902Phase 2
- Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00042913Phase 2
- Epratuzumab in Treating Patients With Non-Hodgkin's LymphomaStatus unknownNCT00022685Phase 3
- Humanized LL2IGG to Treat Systemic Lupus ErythematosusCompletedNCT00011908Phase 1